isoxazoles has been researched along with Cardiac Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frangogiannis, NG; Fujikura, K; Garcia, MJ; Palanski, BA; Shinde, AV; Su, Y | 1 |
| Block, N; Brock, TA; Chen, SJ; Chen, YF; Dixon, RA; Munsch, CL; Sherwood, SJ; Tilton, RG; Wu, C | 1 |
2 other study(ies) available for isoxazoles and Cardiac Hypertrophy
| Article | Year |
|---|---|
Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure overload.
Topics: Animals; Cardiomegaly; Collagen; Diastole; Extracellular Matrix; Female; Fibroblasts; Fibrosis; GTP-Binding Proteins; Hypertrophy, Left Ventricular; Isoxazoles; Male; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Pressure; Protein Glutamine gamma Glutamyltransferase 2; Pyrrolidines; Quinolines; Recombinant Proteins; Stroke Volume; Tissue Inhibitor of Metalloproteinases; Transcription, Genetic; Transglutaminases; Up-Regulation; Ventricular Remodeling | 2018 |
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Isoxazoles; Male; Monocrotaline; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Thiophenes; Vasoconstriction; Weight Gain | 2000 |